Article: Barr Receives Approval for Generic Version of Razadyne(R) ER Capsules.

MONTVALE, N.J., Sept. 16 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. today announced that its subsidiary, Barr Laboratories, Inc., received final approval from the U.S. Food & Drug Administration (FDA) to manufacture and market a generic version of Ortho McNeil Janssen's Razadyne(R) ER (galantamine hydrobromide extended release capsules), eq. to 8 mg, 16 mg and 24 mg. Barr also announced that it is the first company to file an Abbreviated New Drug Application (ANDA) with the U.S. Food & Drug Administration (FDA) containing a Paragraph IV certification for a generic version of Razadyne ER capsules, and therefore is entitled to 180-days of marketing exclusivity, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!